About Chaperone Technologies
Chaperone Technologies, Inc. is developing antimicrobial products, based on a novel and proprietary mechanism of action, for difficult-to-treat and drug-resistant organisms across a broad range of infectious diseases. Chaperone's proven technology has already yielded the company's first product, a potent antimicrobial which is in development for treating complicated drug resistant Urinary Tract Infections.
Chaperone Technologies Frequently Asked Questions (FAQ)
Where is Chaperone Technologies's headquarters?
Chaperone Technologies's headquarters is located at 1200 Liberty Ridge Drive, Wayne.
What is Chaperone Technologies's latest funding round?
Chaperone Technologies's latest funding round is Unattributed VC.
How much did Chaperone Technologies raise?
Chaperone Technologies raised a total of $100K.
Who are the investors of Chaperone Technologies?
Investors of Chaperone Technologies include Life Sciences Greenhouse of Central Pennsylvania.
Who are Chaperone Technologies's competitors?
Competitors of Chaperone Technologies include Aphios, Sagimet Biosciences, Pfenex, Hawaii Biotech, Array Biopharma and 7 more.
Compare Chaperone Technologies to Competitors
Zetra Biologicals is a preclinical stage biopharmaceutical company developing vaccines against pandemic influenza and other infectious diseases.
SensiGen is a company focused on women's health and genetic testing within the healthcare sector. They offer a comprehensive range of diagnostic tests and genetic counseling services designed to support women at various stages of their reproductive journey. The company primarily serves the healthcare industry, catering to both individual patients and healthcare providers. It was founded in 2002 and is based in Ann Arbor, Michigan.
TargAnox offers therapeutics to treat diseases resulting from oxidative stress-induced protein aging
Neugenesis Corporation is focused on generating better biotherapeutics, cost-effectively. To this end, Neugenesis has developed technology for the discovery, improvement and production of complex proteins; especially heteromeric proteins. The Company's work with the filamentous fungi Neurospora crassa has resulted in significant advances in three important areas of biotechnology: directed evolution, combinatorial biology and recombinant protein expression.
AM-Pharma is a biopharmaceutical company that focuses on developing treatments for severe medical conditions. The company's main offerings include the development of a proprietary compound for the treatment of cardiac surgery-associated renal damage and hypophosphatasia, a rare disease. The company primarily serves the healthcare industry. It was founded in 2001 and is based in Utrecht, Netherlands.
Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).